Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $22.50.
COGT has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Cogent Biosciences in a research report on Wednesday, August 30th. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, August 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, September 19th.
Institutional Investors Weigh In On Cogent Biosciences
Cogent Biosciences Stock Down 5.6 %
COGT stock opened at $7.53 on Thursday. The company’s 50-day simple moving average is $9.18 and its 200-day simple moving average is $11.05. Cogent Biosciences has a 52-week low of $6.48 and a 52-week high of $15.68. The firm has a market cap of $648.51 million, a P/E ratio of -3.23 and a beta of 1.66.
Cogent Biosciences Company Profile
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
- Five stocks we like better than Cogent Biosciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- The most upgraded stocks in November have two things in common
- How to Invest in Esports
- Monday.com rocked earnings like it’s the weekend
- The How and Why of Investing in Biotech Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.